The Alzheimer’s Association, Georgia Chapter is now offering statewide Theatre Thursdays, a virtual theatre program developed for people with Mild Cognitive Impairment (MCI), Early Stage Alzheimer’s or dementia.
Individuals who reside in louder regions are more at risk of developing Alzheimer’s, new report shows.
A sound-level spike of only 10 decibels raised the risk by 30 percent. That is the gap between breathing and whispering. It also culminated in 36 percent greater chances of moderate cognitive disability, including memory and reasoning ability, scientists said.
Twenty Veterans with Alzheimer’s disease and apathy took part in a pilot study. Half received repetitive transcranial magnetic stimulation (rTMS), a type of brain stimulation. The others received sham stimulation, basically a placebo.
Through patient and caregiver interviews, the VA team documented “significantly greater improvement” in apathy levels in those who received brain stimulation compared with the control group. The positive effects continued up to three months.
Besides improvements in apathy, the researchers also noted “significantly greater improvement” in memory, attention, and cognition in the rTMS patients compared with the sham treatment group.
The writer of the post in our link for today developed an approach that allowed us to activate the neurons that store memory information, referred to as memory engrams, through optogenetics—that is, introducing a gene that is light sensitive into the memory engram cells of “Alzheimer’s” mice, then delivering blue light pulses to activate them—and measuring memory recall strength directly. To our surprise, we found comparable numbers of engram cells in normal healthy animals and Alzheimer’s animals, suggesting that the initial memory storage process is intact. Targeting the recall process in Alzheimer’s animals led to an improvement in their memory, which reached the performance level of normal animals.
Supporting demented patients, who are mostly unresponsive, without making demands or asking a question and regarding them as valuable human beings unexpectedly improve their memory performance around the time of death.
In this time, where resources and support are either not available, or, have restrictions that make them difficult to access, the Alzheimer’s Association® 24/7/Helpline (800.272.3900) is available around the clock, 365 days a year. Through this free service, specialists, and master’s – level clinicians offer confidential support and information to people living with the disease, caregivers, families, and the public.
Navigating the Holidays with someone who has Alzheimer’s can be tricky. The current pandemic is certainly not helping either. But Pam Myers, program director for the Alzheimer’s Association Northwest Ohio Chapter, said caregivers need to look for ways to de-stress by creating new traditions and finding new ways for their family members to help make this season satisfying for all. See her tips in our link for today.
Feelings of apprehension and fear are often observed in those suffering mild cognitive impairment (MCI), and previous research has suggested that anxiety could be an early indicator for Alzheimer’s disease, which often follows MCI. Now a new study has found an association between anxiety and an increased rate of progression from MCI to Alzheimer’s disease.
A company has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also raises concern about the accuracy and impact of such life-altering news.
Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.
Preparing for the holidays can be a sweet time together. But part of managing expectations involves staying focused on the task rather than the outcome. Mix batter, decorate cookies, open holiday cards or make simple decorations.
A study released Wednesday by USC researchers found that older women who live in areas with high levels of air pollution may have more Alzheimer’s-like brain shrinkage than those who live in places with cleaner air.
Start a Facebook fundraiser and CVS Health will give $10 Support the Association by starting a #GivingTuesday Facebook fundraiser today, and CVS Health will kick off your efforts with a $10 donation. In addition, donations made to your fundraiser on #GivingTuesday (Dec. 1) are eligible for a match from Facebook. The funds you raise help to provide Alzheimer’s care and support and accelerate critical research.
Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.
The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.
The first blood test designed to assist physicians in determining whether a patient has Alzheimer’s disease is now available in most US states, the company C2N Diagnostics announced October 29. The test measures biomarkers that frequently reflect the presence of amyloid plaques in the brain—a hallmark of Alzheimer’s—as well as the presence of a gene variant that increases the risk of the disease.
An artificial intelligence (AI) tool was able to accurately predict Alzheimer’s disease almost eight years before a person was diagnosed, according to a study recently published in the journal EClinicalMedicine, and researchers say the tool could help providers to identify patients in early stages of the disease.
Great article from theadvocate about various misconceptions over Alzheimer’s. Best quote:
One of the most pervasive misconceptions is that a diagnosis of Alzheimer’s disease means that all hope is lost, and that life is over. Though it will mean changes, the affected individual and his or her family are often able to find new communities of support and learn how to live with the disease to continue meaningful and purposeful lives.
Where lots of studies have been halted due to the pandemic, the large study at the the Institute for Memory Impairments and Neurological Disorders at the University of California, Irvine is moving forward cautiously.
Read the article in our link for today to learn about how they assure the safety of the participants in the study.
Immunotherapy is the prevention or treatment of disease with drugs that stimulate an immune response. Scientists are looking for a cure to Alzheimer’s disease that boosts our immune systems. Administering drugs to elicit an immune response works in a similar way to a vaccine and pharmaceutical companies are placing bets on immunotherapy to target Alzheimer’s disease.